Xueli Yang1,2, Zhengquan Zhang3, Xiaoqing Jia2, Yanqin Zhang1, Tianyang Mu1, Bingzheng Zhou1, Lin Li1, Deyuan Fu3, Xin Hu2, Shunbin Xiong1,4. 1. Department of Cancer Stem Cell, Dalian Medical University, Dalian 116000, China. 2. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200030, China. 3. Department of Thyroid and Breast Surgery, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China. 4. Department of Genetics, M.D. Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA.
Abstract
BACKGROUND: PLA2G16 functions as a phosphatase in metabolism and its abnormal expression is closely associated with tumor progression. The aim of this study is to investigate the prognosis value of PLA2G16 in breast cancer. METHODS: A tissue microarray including 200 invasive ductal carcinoma specimens was constructed. Immunohistochemistry was performed to determine the PLA2G16 expression status. The Kaplan-Meier analysis and log-rank test were used to evaluate the prognostic value of PLA2G16. The Multivariate Cox regression analysis was performed to identify whether PLA2G16 was an independent prognostic factor. RESULTS: In our retrospective study, Kaplan-Meier analysis showed that elevated PLA2G16 expression was correlated with improved DFS (P=0.032) in the whole breast cancer patients. In further subgroup analysis, PLA2G16 overexpression was found to be associated with prolonged DFS (P=0.018) in HER2-positive breast cancer patients. More importantly, Multivariate analysis suggested that PLA2G16 was a significant independent prognostic factor in HER2-enriched patients [hazard ratio (HR) =0.151; 95% confidence interval (CI) =0.034-0.672; P=0.013]. CONCLUSIONS: Our study evaluated the prognostic significance of PLA2G16 in patients with HER2-positive breast cancer and confirmed the relevance of this metabolism-related gene in patient outcome.
BACKGROUND:PLA2G16 functions as a phosphatase in metabolism and its abnormal expression is closely associated with tumor progression. The aim of this study is to investigate the prognosis value of PLA2G16 in breast cancer. METHODS: A tissue microarray including 200 invasive ductal carcinoma specimens was constructed. Immunohistochemistry was performed to determine the PLA2G16 expression status. The Kaplan-Meier analysis and log-rank test were used to evaluate the prognostic value of PLA2G16. The Multivariate Cox regression analysis was performed to identify whether PLA2G16 was an independent prognostic factor. RESULTS: In our retrospective study, Kaplan-Meier analysis showed that elevated PLA2G16 expression was correlated with improved DFS (P=0.032) in the whole breast cancerpatients. In further subgroup analysis, PLA2G16 overexpression was found to be associated with prolonged DFS (P=0.018) in HER2-positive breast cancerpatients. More importantly, Multivariate analysis suggested that PLA2G16 was a significant independent prognostic factor in HER2-enriched patients [hazard ratio (HR) =0.151; 95% confidence interval (CI) =0.034-0.672; P=0.013]. CONCLUSIONS: Our study evaluated the prognostic significance of PLA2G16 in patients with HER2-positive breast cancer and confirmed the relevance of this metabolism-related gene in patient outcome.
Entities:
Keywords:
HER2/neu; PLA2G16; breast cancer; disease-free survival
Authors: C M Perou; S S Jeffrey; M van de Rijn; C A Rees; M B Eisen; D T Ross; A Pergamenschikov; C F Williams; S X Zhu; J C Lee; D Lashkari; D Shalon; P O Brown; D Botstein Journal: Proc Natl Acad Sci U S A Date: 1999-08-03 Impact factor: 11.205
Authors: Daniel K Nomura; Jonathan Z Long; Sherry Niessen; Heather S Hoover; Shu-Wing Ng; Benjamin F Cravatt Journal: Cell Date: 2010-01-08 Impact factor: 41.582
Authors: Tariq A Khemees; Bing Yang; Adam Schultz; Glenn O Allen; Joseph Gawdzik; Aman Nihal; Kyle A Richards; E Jason Abel; David F Jarrard Journal: Am J Clin Exp Urol Date: 2021-12-15
Authors: William E Jarrard; Adam Schultz; Tyler Etheridge; Shivashankar Damodaran; Glenn O Allen; David Jarrard; Bing Yang Journal: PLoS One Date: 2019-06-24 Impact factor: 3.240